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Objective: Heparin coating reduces complement activation on the surface of 
extracorporeal circuits. In this study we investigated its effect on activation 
of the contact system in 30 patients undergoing coronary artery bypass 
grafting with the use of a heparin-coated (Duraflo II, Baxter Healthcare 
Corp., Edwards Division, Santa Ana, Calif.; n = 15) or an uncoated 
extracorporeal circuit (n = 15). Methods: Plasma markers that reflect 
activation of contact (kallikrein-Cl-inhibitor complexes), coagulation (pro- 
thrombin fragments F l+2),  or fibrinolytic (plasmin-o~2-antiplasmin com- 
plexes) systems were determined before and during the operation. The 
generation of kallikrein-Cl-inhibitor complexes was reduced by 62% (p = 
0.06) after the onset of cardiopulmonary bypass and by 43% (p = 0.026) 
after the cessation of bypass in the group in which a heparin-coated circuit 
was used compared with the group in which the circuit was uncoated. 
Generation was reduced by 58% (p = 0.06) when the ratio of kallikrein- 
Cllinhibitor to prekallikrein after onset of bypass was considered. We 
detected significant increases in F l+2 levels in both groups and increases 
in plasmin-a2-antiplasmin complexes in the heparin-coated group at 
cessation of bypass, but no intergroup differences were observed. Thus use 
of heparin-coated extracorporeal circuits during cardiac operations re- 
duces formation of kallikrein-Cl-inhibitor complexes when compared with 
use of uncoated circuits. The heparin coating is not accompanied by similar 
reductions in coagulation or fibrinolysis, suggesting that thrombin and 
plasmin formation during cardiopulmonary bypass occurs mainly indepenl 
dently of the contact system activation. (J Thorac Cardiovasc Surg 1997; 
114:117-22) 
D uring cardiopulmonary b pass (CPB) the exten- sive contact between blood and the surface of 
the extracorporeal circuit (ECC) results in activa- 
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tion of various humoral and cellular cascades. 
Blood-material interaction causes activation of clot- 
ting in recipients, which necessitates simultaneous 
pretreatment with coagulation inhibitors such as 
heparin sulfate. This observation has led to the 
development of surface coatings with heparin on the 
vital compartments of the ECCs. Since heparin- 
coated ECCs became commercially available, stud- 
ies have been performed regarding the effects of 
heparin coating on the generation of complement 
activation products. 1-3 Remarkably, no clinical study 
has so far been published regarding its effect on 
activation of the contact system, that is, the initia- 
tion of the intrinsic pathway of coagulation and 
fibrinolysis. 
The contact system is initiated when factor XI I  
(FXII, Hageman factor) binds to negatively charged 
surfaces and subsequently becomes activated 
(FXIIa).4, 5 FXI Ia can cleave factor XI  (FXI) of the 
intrinsic coagulation pathway into FXIa, which 
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eventually may trigger thrombin formation and clot- 
ting. FXI Ia can also cleave prekallikrein into kal- 
likrein, which cleaves high-molecular-weight kinin- 
ogen to release bradykinin, a nonapeptide with 
notorious vasodilating properties. 4' 5 FXI Ia may fur- 
ther be cleaved by kallikrein into Hageman factor 
fragment (/3-FXIIa). Hageman factor fragment (and 
not FXIIa) in its turn may enzymatically activate the 
first component of the classic complement pathway, 
C1. 6 Contact activation is mainly controlled by C1- 
esterase inhibitor (ClInh), which forms stable and 
detectable complexes with FXIIa, FXIa, and kal- 
likrein.7, s
To evaluate the activation of the contact system 
during CPB and the effect of heparin coating on this 
activation, we performed a randomized trial in 30 
patients undergoing coronary bypass operations 
who were connected to either a heparin-coated or
an uncoated ECC. We determined plasma markers 
for contact activation, coagulation, and fibrinolysis 
before and during the operation. 
Materials and methods 
Patients and study design. We performed a prospec- 
tive study to determine whether heparin coating of ECCs 
reduced contact activation. Therefore 30 patients under- 
going elective coronary bypass operations were enrolled 
and randomly allocated to be connected to either a 
heparin-coated (15 patients) or an uncoated ECC (15 
patients). The study was performed at the Department of
Thoracic and Cardiovascular Surgery, C.N.R.S. URA 
1431, and Association Claude Bernard, Henri Mondor 
Hospital, Cr6teil, France, and was approved by the local 
medical and ethics committee. Entry criteria for the study 
were ingestion of aspirin stopped for at least 7 days before 
the operation and left ventricular injection fraction ex- 
ceeding 30%. Exclusion criteria were a history of arrhyth- 
mia, impaired organ function other than myocardial isch- 
emia, and the presence of  active inflammatory disease. 
Patients receiving aprotinin during the operation were 
excluded from the study. 
Techniques of anesthesia nd extracorporeal circula- 
tion. Anesthesia was induced and maintained with phe- 
noperidine and droperidol. The ECC consisted of a roller 
pump (Sarns 9000, 3M Health Care Group, Ann Arbor, 
Mich.), a closed venous reservoir, hollow fiber oxygenator 
(Univox, Baxter Healthcare Corp., Irvine, Calif.), a car- 
diotomy reservoir (Baxter BCR 3500), and an arterial 
filter (Baxter AF-1400). In the heparin-coated ECC 
group, all compartments of the circuit contained surface- 
bound heparin (Duraflo IL, Baxter). The circuits were 
primed with 1000 ml of lactated Ringer's olution, 60 ml 
of 8.4% sodium bicarbonate, 5000 IU of heparin, and 1 
gm of potassium chloride. CPB was performed with core 
cooling to 28 ° C and nonpulsatile flow of 2.4 L • min -~ • 
m -2. During aortic crossclamping, the myocardium was 
protected with antegrade cold cardioplegia. Heparin (300 
IU • kg -1) was administered before cannulation. Addi- 
tional heparin was administered if the activating clotting 
time (ACT, Hemotec, Inc., Englewood, Colo.) was less 
than 600 seconds. After cessation of CPB, protamine 
sulfate (1 mg/100 IU heparin) was administered intrave- 
nously. Blood transfusion was indicated when the hemat- 
ocrit value was below 25%. 
Biochemical parameters. Blood samples were taken 
from the radial artery or from the arterial line of the ECC. 
The samples were immersed in melting ice immediately 
after collection and processed within i hour. Platelet-poor 
plasma samples were prepared by centrifugation for 15 
minutes at 1500g and stored at -70 ° C. Blood samples 
were collected in tubes containing ethylenedinitrotetra 
acetate for anticoagulation (final concentration 10mmol/L). 
Plasma samples for contact activation markers were col- 
lected in tubes containing ethylenedinitrotetra acetate 
supplemented with 0.05% (w/v) of hexadimethrine bro- 
mide (Polybrene; Janssen Pharmaceutica, Beerse, Bel- 
gium). The blood samples were taken before induction of 
anesthesia, 10 minutes after onset of CPB, and within 
minutes after cessation of CPB. 
Factor XIIa-Cl-esterase inhibitor (FXIIa-ClInh) and 
kallikrein-Cl-esterase inhibitor (kal-ClInh) complexes 
were assayed by radioimmunoassay as described before. 8
In brief, a monoclonal antibody that specifically binds 
complexed ClInh (KOK 12) was coupled to CNBr-Sepha- 
rose 4B (Pharmacia Biotech. AB, Uppsala, Sweden) and 
incubated with plasma samples. Bound FXIIa-ClInh or 
kal-ClInh complexes were quantitated by subsequent 
incubation with either 125I-labeled polyclonal anti-FXII or 
125I-labeled anti-kallikrein antibodies, respectively. Re- 
sults obtained with tested plasma were calculated by 
reference to an in-house standard curve that consisted of 
kaolin-stimulated pooled plasma. Prekallikrein antigen 
was assayed by radioimmunoassay as described before. In 
brief, plasma samples were incubated with a specific 
anti-prekallikrein monoclonal antibody (K15) coupled to 
sepharose. Bound prekallikrein was quantitated with 125I- 
labeled polyclonal antibodies (636) against prekallikrein. 
We calculated the ratio between the activation product 
kaUikrein (kal-Cllnh) and its precursor prekallikrein to 
correct for dilution. 
Plasmin-a2-antiplasmin complexes were assayed by ra- 
dioimmunoassay s described before) ° In brief, samples 
were incubated with a Sepharose-coupled monoclonal 
antibody AAP-11, which is directed against complexed 
and inactivated a2-antiplasmin. Bound plasmin-a2-anti- 
plasmin complexes were quantitated with 125I-labeled 
monoclonal antibodies against plasmin (AP1). Serial di- 
lutions of urokinase-activated pooled plasma served as a 
standard. Prothrombin fragment F1 + 2 was measured with 
a commercially available nzyme-linked immunosorbent 
assay (F1+2 ELISA, Behringwerke, Marburg, Germany). 
Data management and statistics. Data were analyzed 
with STATVIEW SE + Graphics computer software (Aba- 
cus Concepts, Inc., Berkeley, Calif.). Comparisons within 
the groups were assessed with the paired t test and 
between the groups with regression analysis. The adjusted 
R 2 for the regression analysis is given and the coefficients 
are expressed within 95% confidence limits. Dichotomous 
variables were analyzed with Fisher's exact test. In all 
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Table I. Patient's characteristics, urgical data, and 
blood loss 
Heparin- 
Uncoated coated 
ECC ECC p Value 
Age (yr) 64 + 3.4 65 -+ 4.0 NS 
Sex (female/male) 1/14 5/10 NS 
Height (m) 1.67 _+ 5 1.65 + 6 NS 
Weight (kg) 77 -+ 7 67 _+ 6 0.02 
Body surface area (m 2) 1.93 + 0.1 1.78 -+ 0.1 0.02 
Duration of crossclamping 71 -+ 13 71 -+ 12 NS 
(rain) 
Duration of CPB (min) 129 _+ 18 138 -- 26 NS 
Data are presented as means -+ 95% confidence of the mean. NS, Not 
significant. 
cases a two-sided probability less than 0.05 was considered 
to be significant. Data are presented as means + 95% 
confidence interval of the mean and are not corrected for 
hemodilution unless mentioned otherwise. 
Results 
Demographic data and surgical data of both 
groups are listed in Table I. No complications 
occurred and all patients survived. The patients 
were randomly allocated to be connected either to 
an uncoated or a heparin-coated ECC. The patients 
in the uncoated ECC group appeared heavier (p = 
0.02) and had a larger body surface area (p = 0.02). 
After onset of CPB, levels of kal-Cllnh com- 
plexes were 62% lower in the heparin-coated group 
(p = 0.058). After cessation of CPB, levels of 
kal-ClInh complexes were significantly lower in the 
heparin-coated ECC group than in the uncoated 
group (difference 43%;p = 0.026) (Fig. 1, Table II). 
This difference in kal-ClInh was related only to the 
heparin coating (adjusted R2: 0.41; 95% confidence 
interval of the coefficient [CI]: -185, -16), while 
baseline (95% CI: -0.054, 0.38), duration of CPB 
(95% CI:-0.36, 2.2), and body weight (95% CI: -38, 
4.8) did not contribute. Thus the patient's body 
weight did not contribute to differences found in 
contact activation between the groups. After onset 
of CPB and at cessation of CPB, prekallikrein 
concentrations dropped equally in the two groups 
(Table II), parallel with dilution, without significant 
intergroup differences. Also, after correction for 
hematocrit values, prekallikrein levels slightly 
dropped by 6% to 10% (p > 0.05) in both groups 
during CPB (Table II). We calculated the ratio 
between kal-ClInh complex and prekallikrein. Only 
0.025% to 0.05% of all prekallikrein is cleaved into 
kallikrein. In the heparin-coated ECC group, this 
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Fig. 1. Kallikrein-Cl-inhibitor complexes, plasmin-anti- 
plasmin complexes, and F1+2 concentrations during 
CPB. Data presented are means with 95% confidence 
interval of the mean. Open bars, Uncoated ECCs; closed 
bars, heparin-coated ECCs. *p = 0.026, intergroup differ- 
ences; #p = 0.014; ~:p = 0.015 compared with preopera- 
tive values. 
ratio remained unchanged uring CPB, whereas in 
the uncoated ECC group a significant increase was 
determined at cessation of CPB (p = 0.014). Most of 
the values for FXIIa-Cllnh complexes were below 
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Table II. Blood activation markers and hematocrit values in patients undergoing CPB with an uncoated or a 
heparin-coated ECC 
ECC Preoperative After start of CPB End of CPB 
Hematocrit (%) Uncoated 41 (1.5) 29 (3.2)'~ 30 (1.9)'~ 
Heparin coated 38 (3.1) 28 (3.0)~" 29 (1.3)'~ 
PK (nmol/L) Uncoated 407 (61) 261 (59)t 259 (33)t 
Heparin coated 367 (59) 243 (34)'{" 237 (38)t 
PK corr. Hct Uncoated 407 (61) 373 (59) 373 (33) 
Heparin coated 367 (59) 349 (34) 333 (38) 
Kal-Cllnh (pmol/L) Uncoated 165 (57) 154 (86) 212 (77)* 
Heparin coated 174 (142) 58 (20) 120 (32) 
Ratio Kal-CII/PK (× 10 -4) Uncoated 4.3 (1.7) 5.7 (2.6) 8.7 (3.2)~: 
Heparin coated 4.2 (2.5) 2.4 (0.7) 5.3 (1.6) 
F1 +2 (nmol/L) Uncoated 0.58 (0.06) 0.68 (0.11) 1.37 (0.38)§ 
Heparin coated 0.58 (0.05) 0.67 (0.11) 1.21 (0.38)§ 
PAP (nmol/L) Uncoated 9 (2) 13 (11) 23 (20) 
Heparin coated 12 (4) 14 (7) 40 (22)11 
Data are presented as means (95% confidence interval of the mean). PK, prekallikrein; PK corrected for hematocrit according to 
PK(corrected) = PK(sample) - Hct(baseline)/Hct(sample); PAP, plasmin-az-antiplasmin. 
*p = 0.026, intergroup differences. 
tp = 0.001. 
~p = 0.014. 
§p = 0.003. 
liP = 0.015 compared with preoperative. 
the equation: 
the detection limit of the assay, which made it 
impossible to assess differences between the groups. 
We did not determine any intergroup differences 
in F l+2 or plasmin-a2-antiplasmin (Fig. 1, Table 
II). In both groups, F l+2 concentrations increased 
significantly at cessation of CPB (p = 0.003). Plas- 
min-a2-antiplasmin levels, however, increased only 
in the heparin-coated group at cessation of CPB 
(p = 0.015). No correlations were found between 
Fl+2, plasmin-a2-antiplasmin, or kal-ClInh com- 
plexes. 
Discussion 
Despite anticoagulant treatment with heparin, we 
detected clotting activation as reflected by the gen- 
eration of the prothrombin fragment F l+2 during 
CPB. In addition, plasmin and kallikrein were 
formed during CPB as indicated by the formation of 
plasmin-antiplasmin a d kal-ClInh complexes, re- 
spectively. Although activation of the contact system 
is generally believed to manifest itself strongly dur- 
ing blood-material interaction, as for example dur- 
ing CPB, only Wachtfogel and associates 11demon- 
strated kallikrein formation in patients undergoing 
CPB, but only after the ECC had been discon- 
nected. Furthermore, Kongsgaard, 12 De Smet, 13 and 
their associates reported a transient decrease in 
kallikrein-inhibiting capacity immediately after hep- 
arinization and onset of CPB. Thus surprisingly little 
evidence for contact activation during CPB exists, 
although during simulated ECC kal-ClInh com- 
plexes are formed immediately after the start of the 
ECC procedure. TM14, 15 The increase in the ratio 
between kal-ClInh and prekallikrein in our patients, 
when connected to an uncoated circuit, is consistent 
with contact activation during simulated ECC. The 
increase, however, was only moderate, which in part 
may have been due to rapid clearance of the kal- 
ClInh complexes. 
In this study, we studied patients connected to 
either a heparin-coated or an uncoated ECC and 
found an almost significant reduction by 62% in 
kal-ClInh complexes (p = 0.06) in the heparin- 
coated ECC group. This drop in kal-ClInh com- 
plexes in the heparin-coated ECC group was not 
explained by a higher dilution at the onset of CPB, 
because in both groups an identical ratio of kal- 
ClInh complexes to prekallikrein was found before 
and after onset of CPB and the degree of dilution 
was identical in both groups, as reflected by similar 
changes in hematocrit value (see Table II). Evi- 
dently, heparin coating had almost significantly re- 
duced kallikrein formation already after the onset of 
CPB, but significantly at the end of CPB. The 
difference at the end of CPB was explained only by 
the use of heparin coating, whereas blood-contact 
time (duration of CPB), preoperative l vels, and the 
patient's body weight did not contribute. 
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The question can be raised by what mechanism 
heparin coating exercises its activity on the contact 
system. The decreased formation of kallikrein in the 
heparin-coated ECC group cannot be explained by 
the potentiating effect of heparin on ClInh activity. 
Although heparin does potentiate Cllnh regarding 
inhibition of complement Cls and Clr activity 16 and 
also of the clotting protease FXIa, 7 it does not 
change the rate of FXII or kallikrein inhibition by 
Clinh.17, 18 However, in the presence of unfraction- 
ated heparin and high-molecular-weight kininogen, 
kallikrein is mainly inhibited by antithrombin III 
(50% to 53%), 19' zo while inhibition by ClInh drops 
from 45% (without heparin) to 24% (with heparin) 
and that by o~2-macroglobulin from 55% to 22%. 
Thus a shift in kallikrein-inhibitor complexes after 
heparinization in favor of kallikrein-antithrombin 
III complexes might explain the drop in kal-ClInh 
complexes after the onset of CPB. In the uncoated 
ECC group, this drop is masked by additional 
kallikrein formation on the surface of the circuit. 
The net result is more or less stable concentrations 
of complexes. Consistent with this finding are the 
observations that antithrombin III, and not Cllnh, 
seems to be the most important antiprotease during 
the control of contact activation on heparin-coated 
surfaces in vitro. Sanchez and colleagues 21observed 
clot formation on the surface of heparin-coated 
polyethylene tubings with recalcified plasma de- 
pleted of antithrombin III, but not with ClInh- 
depleted plasma. Moreover, removal of antithrom- 
bin III resulted in extensive activation of FXII, 
whereas ClInh depletion had lesser effects. 21 The 
reduced generation of kal-Cllnh complexes may 
thus be due to enhanced activity of antithrombin III 
by the surface-immobilized heparin that inhibits 
kallikrein activity, enhancement of FXII activation, 
and thus contact activation. 
A second, and more simple, explanation would be 
that heparin covers the surface of the circuits and 
thus prevents FXII binding. 
It is believed that during CPB thrombin formation 
is mainly initiated through the activation of the 
contact system. Intensive contact between blood and 
the surface of the ECC initiates activation of FXII 
and, subsequently, that of factors of the intrinsic 
pathway of coagulation. Heparin coating reduces 
material-dependent thrombin formation by an anti- 
thrombin III-dependent mechanism. 22' 23 However, 
the application of heparin-coated ECCs did not 
reduce thrombin formation during CPB, as we as- 
sessed by measuring the course of prothrombin 
fragment F1+2. Considering that contact activation 
was reduced by heparin coating of the circuits, our 
findings imply that thrombin formation occurs inde- 
pendently from contact activation. This is supported 
by several other studies. 24-26 Thrombin formation 
during CPB probably mainly occurs via the tissue- 
factor pathway and may be independent of the use 
of heparin-coated ECCs. In agreement herewith, 
patients with a severe FXII deficiency undergoing 
cardiac surgery show comparable thrombin forma- 
tion to normal individuals. 27' 28 Conversely, activa- 
tion of the contact system seems to be related to 
fibrinolysis. Patients with a severe FXII deficiency 
(FXII < 1%) demonstrate impaired fibrinolytic 
activity after desamino D-arginine vasopressin stim- 
ulation 29 and may have a higher incidence of throm- 
boembolism. 3° In the present study, however, we 
found no direct support for involvement of the 
contact system in fibrinolysis. Although kal-Cllnh 
complexes in the heparin-coated ECC group were 
significantly reduced, plasmino~2-antiplasmin levels 
increased instead of reduced. 
In summary, we found reduced formation of 
kallikrein in patients connected to a heparin-coated 
ECC, and no effect on thrombin formation. Thus 
this study further supports the hypothesis that 
thrombin formation during cardiac surgery is not 
induced only via the intrinsic pathway of coagula- 
tion. Additionally, we also found no evidence for 
involvement of contact activation in plasmin forma- 
tion. Thus the contribution and the clinical rele- 
vance of the FXII-induced pathway on blood acti- 
vation in patients undergoing cardiac surgery 
remains to be determined. 
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